Denufosol

Denufosol is a drug developed for the treatment of cystic fibrosis. It is a P2Y2 receptor agonist, meaning it activates a specific type of receptor in the body. The P2Y2 receptor plays a role in regulating the movement of ions, particularly chloride and sodium, across cell membranes. In cystic fibrosis, a genetic disorder affecting the lungs and other organs, the transport of these ions is impaired, leading to the buildup of thick, sticky mucus. Denufosol was designed to restore normal ion transport and improve mucus clearance in the airways. Clinical trials investigated its efficacy and safety as an inhaled therapy. While early research showed some promise in improving lung function, the drug ultimately did not receive regulatory approval for widespread use. Further development and investigation into its therapeutic potential have since been discontinued.